Protocol Ledger

NCT07282574 · Phase II · RECRUITING

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)

Interventional Phase II clinical trial protocol NCT07282574 sponsored by Roche / Genentech in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-03-10 Enrollment: 360 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07282574
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)360 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07282574
Protocol FieldVerified Registry Value
NCT IdentifierNCT07282574
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment360 participants (ESTIMATED)
Registered Start Date2026-03-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07282574
Hospital Research SiteLocationSite Profile
Box Hill HospitalBox Hill, AustraliaOpen Hospital Dossier ->
Austin HealthHeidelberg, AustraliaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI